TB-500 Medicine

REGISTER / CITATIONS

TB-500 references and citations

The full source register behind this console — peer-reviewed thymosin beta-4 studies and the FDA pages underlying the 503A status, each with its identifier.

Back to the researchRead the legal status

How to read this register

Every quantitative claim across this TB-500 console resolves to a numbered source below. Entries 1–15 are peer-reviewed studies and reviews on thymosin beta-4 and its LKKTETQ fragment, each with its PMID or DOI. Entries 16–20 are the FDA and regulatory sources behind the FDA 503A compounding access page. Where a finding rests on full-length thymosin beta-4 rather than the TB-500 heptapeptide, the body copy says so at the point of citation — the distinction is load-bearing throughout this site. Links resolve to PubMed, the journal of record, or FDA.gov.

  1. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  2. Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. ↗
  3. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. ↗
  4. Morris DC, et al. A dose-response study of thymosin β4 for the treatment of acute stroke. J Neurol Sci. 2014;345(1-2):61-67. ↗
  5. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  6. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. ↗
  7. Grant DS, et al. Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis. 2007;10(2):137-145. ↗
  8. Jo JO, et al. Thymosin β4 induces the expression of vascular endothelial growth factor (VEGF) in a hypoxia-inducible factor (HIF)-1α-dependent manner. Biochim Biophys Acta. 2010;1803(11):1244-1251. ↗
  9. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-275. ↗
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  11. Gao X, et al. Thymosin Beta-4 Induces Mouse Hair Growth. PLoS One. 2015;10(6):e0130040. ↗
  12. Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. ↗
  13. Xiao X, et al. Multiple potential roles of thymosin β4 in the growth and development of hair follicles. J Cell Mol Med. 2021;25(3):1350-1358. ↗
  14. Chen Y, et al. Thymosin β4 released from functionalized self-assembling peptide activates cardiac cells and promotes cardiac repair. Theranostics. 2021;11(10):4974-4986. ↗
  15. Zhang Y, et al. Tβ4-exosome-loaded hemostatic and antibacterial hydrogel to improve vascularized wound repair. Mater Today Bio. 2025;32:101585. ↗
  16. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (entry: "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500"; Category 2, effective with the September 29, 2023 update). ↗
  17. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (503A/503B framework; Category 1 and Category 2 definitions; nomination and PCAC process). ↗
  18. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda listing "TB-500 (free base)" / "TB-500 acetate," alongside BPC-157, KPV, and MOTs-C, as substances being considered for inclusion on the 503A Bulks List; scheduled discussion, not a decision). ↗
  19. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (finalized January 2025); note: reported early-2026 reclassification of Category 2 peptides could not be confirmed as a completed, effective FDA action as of 2026-05-29 and is not stated here as fact. ↗
  20. U.S. Food and Drug Administration. Compounding pathway under Sections 503A and 503B of the FD&C Act: licensed-prescriber evaluation (including compliant telehealth as a front-end channel), valid patient-specific prescription, dispensing by a state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility, subject to bulk-substance ingredient eligibility. ↗